Amendments to the Claims

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1. (Original) A compound of the formula

$$R^4$$
— $(CH_2)_n$ — Y
 R^0
 R^2
 R^3
 R^1
 (I)

wherein

 R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);

 R^{O} , R^{2} and R^{3} are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R⁴ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

X is -S- or -HC=CH-; and

Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

or a pharmaceutically acceptable salt thereof.

4

2. (Original) A compound of the formula

$$R^4$$
 $(CH_2)_n$ Y R^2 R^3 (I)

wherein

 R^1 is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C2-C6 alkyl);

 R^2 and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R⁴ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

X is -S- or -HC=CH-; and

Y is -O-, -S-, -NH-, -NMe-, or $-CH_2$ -;

or a pharmaceutically acceptable salt thereof.

- 3. (Presently Amended) A compound according to €laims 1 or 2 €laim 2 wherein Y is –O-.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 3 wherein n is 2.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 4 wherein R¹ is -OH or -OCH₃.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 5 wherein R¹ is -OH.

- 7. (Presently Amended) A compound according to any one of Claims 1-to 3

 Claim 6 wherein R⁴ is 1-piperidinyl or 1-pyrrolidinyl.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 7 wherein R⁴ is 1-piperidinyl.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 8 wherein one of R² and R³ is -H.
- (Presently Amended) A compound according to any one of Claims 1 to 3
 Claim 8 wherein one of R² and R³ is -H and the other is -OH.
- 11. (Presently Amended) A compound according to any one of Claims 1 to 3

 Claim 9 wherein both R² and R³ are -H.
- 12. (Presently Amended) A compound according to any one of Claims 1 to 3.

 Claim 11 wherein X is -S-.
- 13. (Presently Amended) A compound according to any one of Claims 1 to 3

 Claim 11 wherein X is -HC=CH-.
- 14. Cancelled
- 15. (Original) A compound according to Claim 1 wherein said compound is 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol or a pharmaceutically acceptable salt thereof.

16. (Presently Amended) A pharmaceutical composition comprising a compound according to any one of Claims 1 to 15 Claim 15, or a pharmaceutically acceptable salt thereof, and optionally an effective amount of estrogen and progestin, in combination with a pharmaceutically acceptable salt, carrier, diluent, or excipient.

17-39 Presently Cancelled

Respectfully submitted,

Gilbert T. Voy

Attorney for Applicant Registration No. 43,972

Phone: 317-276-2966

Eli Lilly and Company Patent Division/GTV Lilly Corporate Center Indianapolis, Indiana 46285

mach 11, 2005